Literature DB >> 8149539

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

J Sandoval1, O Bauerle, A Palomar, A Gómez, M L Martínez-Guerra, M Beltrán, M L Guerrero.   

Abstract

BACKGROUND: The prognosis of patients with primary pulmonary hypertension (PPH) remains a major problem for the planning and assessment of therapeutic interventions. The objectives of this study were (1) to characterize mortality in a Mexican population of patients with PPH and to investigate factors associated with survival and (2) to test the applicability in this population of the prognostic equation proposed by the US National Institutes of Health study on PPH. METHODS AND
RESULTS: A dynamic cohort of patients with PPH at our institution were enrolled between June 1977 and August 1991 and prospectively followed at regular intervals through September 1992. Measurements at diagnosis included hemodynamic and pulmonary function variables in addition to information on demographic data and medical history. The response to vasodilator treatment was also analyzed. The estimated median survival of the group was 4.04 years (95% confidence interval, 2.98 to 5.08 years). Variables associated with poor survival (univariate analysis) included an elevated mean right atrial pressure, a decreased cardiac index, and a decreased mixed venous PO2. A reduced forced vital capacity and the absence of vasodilator treatment were also associated with poor survival. A multivariate Cox proportional-hazards regression analysis was used to assess the adjusted hazard ratios, hence the relative contributions of the variables controlling for confounding. Reduced forced vital capacity and cardiac index and increased right atrial pressure were still significantly associated as risk factors for survival in patients with PPH. Survival as computed by the equation correlated with real survival of PPH patients with positive predictive values of 87%, 91%, and 89% at 1, 2, and 3 years, respectively. The equation, however, was relatively unable to predict deaths in our population, in part because of the strict limits of poor prognosis.
CONCLUSIONS: Mortality in PPH is largely associated with hemodynamic variables that assess right ventricular function. The proposed prognostic equation had a high sensitivity and a relatively low specificity to predict survival in our PPH population. To improve this specificity it may be necessary to increase the limits of poor prognosis as defined by the equation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149539     DOI: 10.1161/01.cir.89.4.1733

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  87 in total

1.  Characterization of von Willebrand factor in primary pulmonary hypertension.

Authors:  M T Collados; J Sandoval; S López; F A Massó; A Páez; J R Borbolla; L F Montaño
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

Review 2.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

3.  Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.

Authors:  Matthew R Lammi; Stephen C Mathai; Lesley Ann Saketkoo; Robyn T Domsic; Christine Bojanowski; Daniel E Furst; Virginia D Steen
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

Review 4.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

5.  Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome.

Authors:  Nili Zafrir; Boris Zingerman; Alejandro Solodky; Daniel Ben-Dayan; Alex Sagie; Jaqueline Sulkes; Israel Mats; M R Kramer
Journal:  Int J Cardiovasc Imaging       Date:  2006-09-14       Impact factor: 2.357

6.  Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.

Authors:  John H Wlodarczyk; Leslie G Cleland; Anne M Keogh; Keith D McNeil; Kate Perl; Robert G Weintraub; Trevor J Williams
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

8.  Management of Right Ventricular Failure in Pulmonary Hypertension (and After LVAD Implantation).

Authors:  Brittany Palmer; Brent Lampert; Michael A Mathier
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

9.  Are hemodynamics surrogate end points in pulmonary arterial hypertension?

Authors:  Corey E Ventetuolo; Nicole B Gabler; Jason S Fritz; K Akaya Smith; Harold I Palevsky; James R Klinger; Scott D Halpern; Steven M Kawut
Journal:  Circulation       Date:  2014-06-20       Impact factor: 29.690

Review 10.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.